WARMINSTER, Pa. , July 19, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its second quarter financial results, conference call and webcast for Thursday, August 2,

First Subject Dosed in Phase 1 Study of AB-506, Arbutus’ Second-Generation Capsid Inhibitor All-Oral Combination Study of AB-506 and AB-452 Expected in 2019 HBsAg Reduction Data from ARB-1467 Expected in Q4 Arbutus Spinout Genevant Enters Transformative Partnership with Leading mRNA Therapeutics

VANCOUVER, British Columbia and WARMINSTER, Pa. , June 18, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will present at the first annual Roivant Pipeline Day on July 10, 2018

VANCOUVER, British Columbia and WARMINSTER, Pa. , June 07, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the appointment of David Hastings as Chief Financial Officer, effective June

Two Novel HBV Candidates Planned to Enter Clinical Development in 2018 GalNAc Conjugated RNAi Agent Nominated to Enter IND-Enabling Studies Strategic Partnership with Roivant to Launch Genevant, an RNA Therapeutics Company Company to Host a Corporate Update Conference Call Today at 4:30 PM ET

VANCOUVER, British Columbia and WARMINSTER, Pa. , April 30, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, May 3, 2018 at 1:30 PM

Capsid inhibitor with HBV RNA Destabilizer Demonstrate Complementary Efficacy Results Subcutaneous RNAi Agent Demonstrates Durable HBsAg Reduction Following a Single Dose VANCOUVER, British Columbia and WARMINSTER, Pa. , April 12, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation

Genevant aims to advance 5-10 product candidates into the clinic by 2020 across RNAi, mRNA, and gene editing modalities using Arbutus’ LNP and ligand conjugate platforms Genevant will be led by Executive Chairman Paris Panayiotopoulos , former CEO of ARIAD Pharmaceuticals through its 2017

VANCOUVER, British Columbia and WARMINSTER, Pa. , March 28, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced presentation of data at the 53rd Annual International Liver Congress of the

ARB-1467 Phase II Combination Study Beginning in 1Q18 Two New Drug Candidates Planned to Enter Clinical Development in 2H18 Over $200M in Cash Available to Fund Development of HBV Assets Company to Host a Corporate Update Conference Call Today at 4:30 PM ET VANCOUVER, British Columbia and...